2023 World Conference on Lung Cancer (Posters)-EP06.06. Comparison of RICTOR FISH and Rictor Immunohistochemistry in Lung Squamous Cell Carcinoma

EP06.06. Comparison of RICTOR FISH and Rictor Immunohistochemistry in Lung Squamous Cell Carcinoma - PDF(Slides)

Pdf Summary

Researchers compared two methods, RICTOR FISH and Rictor immunohistochemistry, to detect RICTOR amplification in lung squamous cell carcinoma (SQCC). RICTOR amplification occurs in about 15% of lung SQCC cases and can lead to hyperactivation of mTORC2, making it a potential target for therapy. <br /><br />In this study, FISH was performed to detect RICTOR amplification and immunohistochemistry was used to assess Rictor protein expression in 46 cases of lung SQCC. The results were supported by an analysis of a publicly available data set of 511 lung SQCC cases. <br /><br />The researchers found that RICTOR amplification was observed in 20% of the lung SQCC cases, while Rictor membrane staining was seen in 17%. The correlation between RICTOR amplification detected by FISH and Rictor membrane staining was high, with a specificity of 95% and sensitivity of 77%. This correlation was also observed in the analysis of the larger data set. RICTOR copy numbers were found to correlate with Rictor mRNA and protein expression. <br /><br />Based on these findings, the researchers suggest that Rictor immunohistochemistry can potentially be used as a surrogate marker to identify lung SQCC cases with RICTOR amplification, who may benefit from mTORC2 inhibitor therapy. <br /><br />Overall, this study highlights the potential of Rictor immunohistochemistry as an alternative method to detect RICTOR amplification in lung SQCC, providing an additional tool for selecting patients for targeted therapy.

Asset Subtitle

Andras Khoor

Meta Tag

Speaker Andras Khoor

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

RICTOR FISH

Rictor immunohistochemistry

lung squamous cell carcinoma

RICTOR amplification

mTORC2

therapy

FISH

protein expression

correlation

mTORC2 inhibitor